Case Study

Managing Risks In The Development And Manufacture Of Potent Pharmaceuticals Products

Clean Room

Due to perceived and real risks, certain classes of pharmaceutical products have historically been manufactured in dedicated or segregated, self-contained facilities, in order to mitigate cross-contamination concerns.  Recent market reports suggest there’s an increasing number of niche and orphan drugs in development, rendering dedicated production facilities less practical.  Given the variety of products currently in development, including potent drugs, outsourcing the development and manufacturing to a CDMO experienced in handling a range of products, in a multi-use facility, has proven to be an effective strategy.

VIEW THE CASE STUDY!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of Outsourced Pharma? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
I'm interested in newsletter subscriptions.
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: